Schmitz KS, Comvalius AD, Nieuwkoop NJ, Geers D, et al. A measles virus-based vaccine induces robust chikungunya virus-specific CD4(+) T-cell responses in a phase II clinical trial. Vaccine 2023 Sep 17:S0264-410X(23)01092-7. doi: 10.1016/j.vaccine.2023.
PMID: 37726181